Reversers of the multidrug resistance transporter P-glycoprotein

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 812-817

  Stein, Wilfred D ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Chemosensitizer; Membrane pump; Multidrug resistance; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ANTIMALARIAL AGENT; BIRICODAR; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; CYTARABINE; CYTOTOXIN; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GW 120918; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; N ACETYLDAUNORUBICIN; OC 144 093; PACLITAXEL; PROTEIN INHIBITOR; QUINIDINE; TARIQUIDAR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC KIT; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

BINDING SITES; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; KINETICS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 0036591187     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Koberle B, Masters JR, Hartley JA, Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol (1999) 9(5):273-276.
2. Skovsgaard T: Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res (1980) 40(4):1077-1083.
3. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verrapamil. Cancer Res (1981) 41(5):1967-1972.
4. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phas-I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol (1993) 11(9):1652-1660.
5. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB: Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer (1992) 28(1):28-31.
6. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer (1993) 72(12):3553-3563.
7. List AF, Kopecky KJ, William CL, Head DR, Persons DL, Slovack ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR: Benefit of cyclosporin modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology group study. Blood (2001) 98(12):3212-3220.
8. Watanabe T, Tsuge H, Oh-hara T, Naito M, Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol (1995) 34(2):235-241.
9. Ferry DR, Traunecker H, Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 32A(6):1070-1081.
10. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol (1997) 40(Suppl):S13-S19.
11. Sikic BI: Modulation of multidrug resistance: A paradigm for translational clinical research. Oncology (1999) 13(5A):183-187.
12. Beck WT, Grogan TM, Willman CL, Cordon Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res (1996) 56(13):3010-3020.
13. Ayesh S, Lyubimov E, Algour N, Stein WD: Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical assay. Anticancer Drugs (1996) 7(6):678-686.
14. Ludescher C, Eisterer W, Hilbe W, Hofmann J, Thaler J: Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol (195) 91(3):652-657.
15. Stein WD, Kott MV, Toledano P, Mizrahi L: Measurements, ex vivo in human plasma, of the effectiveness of blockers of multidrug resistance. Proc Am Assoc Cancer Res (2001) 42:Abs 5118.
16. Robey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T, Bates S: Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood (1999) 93(1):306-314. Description and use of the CD56+ surrogate assay for measuring the in vivo effectiveness of P-glycoprotein inhibition.
17. Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM: Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J Clin Oncol (2000) 18(21):3677-3689.
18. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S: Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol (2001) 19(3):832-842. Evidence that concomitant administration of valspodar doubles the pharmacokinetic profile of the cytotoxin paclitaxel, requiring a decrease in the dose given. The effect of the reverser varied greatly among individual patients.
19. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiemik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P: Treatment of poor prognosis AML patients using PSC833 (Valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol (1999) 457:47-56.
20. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI: A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res (2001) 7(5):1221-1229.
21. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M , Drengler R, Stephenson J, Harding MW, Von Hoff DD: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol (1998) 16(9):2964-2976.
22. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD: Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res (2002) 8(2):383-393.
23. Hyafil F, Vergely C, Du Vignaud P, Grand Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res (1993) 53(19):4595-4602.
24. Den Ouden D, Van Den Heuvel M, Schoester M, Van Rens G, Sonneveld P: In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myelom cells. Leukemia (1996) 10(12):1930-1936.
25. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA: Selectivity of the multidrug resistance modulator LY335979, for P-glycoprotien and effect on cytochrome P-450 activities. J Pharmacol Exp Ther (1999) 290(2):854-862. A key paper on the selectivity of LY335979, a promising reverser of P-glycoprotein.
26. Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH: Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol (1998) 56(6):719-727.
27. Dantzig AH, Law KL, Cao J, Starling JJ: Reversal of multidrug resistance by the P-glycoprotein modulator. LY335979, from the bench to the clinic. Curr Med Chem (2001) 8(1):39-50.
28. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P: In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 61(2):749-758. A key paper on the pharmacology of the reverser XR-9576.
29. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD: Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res (2000) 60(11):2964-2972.
30. Stein WD: Kinetics of the multidrug transporter and its reversal. Physiol Rev (1997) 77(2):545-590.
31. Lyubimov E, Lan L-B, Pashinsky I, Ayesh S, Stein WD: Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Anticancer Drugs (1995) 6(6):727-435.
32. Ayesh S, Shao Y-M, Stein WD: Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta (1996) 1316(1):8-18.
33. Shao Y-M, Ayesh S, Stein WD: Mutually co-operative interactions between modulators of P-glycoprotein. Biochim Biophys Acta (1997) 1360(1):30-38.
34. Litman T, Zeuthen T, Skovsgaard T, Stein WD: Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta (1997) 1361(2):169-176. Full description of the complexities of the drug-binding sites of P-glycoprotein based on its ATPase activity.
35. Druley TE, Stein WD, Ruth A, Roninson IB: P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry (2001) 40(14):4323-4331.
36. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R: Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry (2000) 39(39):11901-11906.
37. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R: Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol (2000) 58(3):624-632. Evidence for the complexity of the drug-binding sites on P-glycoprotein.
38. Shapiro AB, Ling V: Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificites. Eur J Biochem (1997) 250(1):130-137. Fully describes the interactions between the R and H sites for drug substrates on P-glycoprotein.
39. Shapiro AB, Ling V: Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol (1997) 53(4):587-596